Efficacy of verapamil inhalation in treatment of COPD

Phase 2

• Conditions: Chronic obstructive pulmonary disease.; Diseases of the respiratory system; J00-J99

• Registration Number: IRCT20170210032478N2
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 14 January 2019

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

All admitted COPD patients
GOLD stage : 1-4

Exclusion Criteria

Pregnancy
Sever hepatic dysfunction
Hypotension
Arrhythmia
Cardiac output less than 40%
Verapamil hypersensitivity
Co- administration of beta adrenergic
Bradicardia
Other respiratory diseases along with COPD
Sever renal dysfunction

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
O2 saturation. Timepoint: Baseline resentment before study and 20 min after administration. Method of measurement: puls oxymetery.;Borg scale. Timepoint: Baseline resentment before study and 20 min after administration. Method of measurement: questionare.

Secondary Outcome Measures

Name	Time	Method
FEV1. Timepoint: Baseline and 20 min after intervention. Method of measurement: Lung Function Test.;FVC. Timepoint: Baseline and 20 min after intervention. Method of measurement: Lung Function Test.;TLC. Timepoint: Baseline and 20 min after intervention. Method of measurement: body box pletismograghy.;Airway Resistant. Timepoint: Baseline and 20 min after imtervention. Method of measurement: Body box pletismography.